SLC5A2 and chronic kidney disease: The DAPA-CKD trial [39] included 270 patients with IgAN (38 with concomitant T2D) [40] and can be considered to be the largest IgAN trial so far, with the potential to provide robust evidence supporting the role of SGLT2 inhibitors in the progression of CKD in IgAN patients [41].